Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Boston Scientific's WATCHMAN FLX Pro trial meets primary endpoints

By Public Technologies
  • Boston Scientific reported positive six-month primary results from the SIMPLAAFY trial of its WATCHMAN FLX Pro left atrial appendage closure device.
  • Aspirin alone and reduced-dose anticoagulant regimens matched dual antiplatelet therapy for stroke protection, with less bleeding, supporting simpler post-implant treatment.
  • The reduced-dose anticoagulant regimen also showed fewer device-related blood clots than dual antiplatelet therapy.
  • Results were presented at Transcatheter Cardiovascular Therapeutics 2026 and simultaneously published in JAMA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611021402PR_NEWS_USPR_____NE86404) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.